PIN Pharma Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
1
- Latest Deal Type
-
2ndary - Private
PIN Pharma General Information
Description
Developer of precision immune stimulants designed to link innate and adaptive immune systems. The company's stimulants target breast and colon cancer to overcome cancer-mediated immune suppression, enabling physicians to perform treatment in an enhanced way.
Contact Information
Website
www.pinpharma.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Primary Office
- 55 Broadway
- Suite 315
- New York, NY 10006
- United States
+1 (212) 000-0000
PIN Pharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Secondary Transaction - Private | 01-Apr-2021 | 00.000 | Completed | Generating Revenue | ||
| 1. Early Stage VC (Series A) | 01-Jan-2012 | 00.000 | 00.000 | 000.00 | Completed | Startup |
PIN Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 00,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 000 |
PIN Pharma Patents
PIN Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2014329393-B2 | Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment | Inactive | 04-Oct-2013 | 0000000000 | |
| AU-2014329393-A1 | Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment | Active | 04-Oct-2013 | 0000000000 | |
| CA-2926221-A1 | Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment | Inactive | 04-Oct-2013 | 0000000000 | |
| EP-3052127-A1 | Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment | Inactive | 04-Oct-2013 | 0000000000 | |
| US-9663556-B2 | Treatment of cancers with immunostimulatory hiv tat derivative polypeptides | Active | 04-Oct-2013 | A61K38/162 |
PIN Pharma Executive Team (4)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Colin Bier Ph.D | Co-Inventor, Chief Executive Officer, Chief Scientific Officer & President | ||
| Joshua Goldberg | Co-Inventor |
PIN Pharma Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| Richard Rathmann | Self | Board Member | 000 0000 |
| William Gedale JD | NGN Capital | Chairman | 000 0000 |
PIN Pharma Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
